Quetiapine for Bipolar Disorder and Alcohol Dependence

Bipolar Disorder Clinical Trial

Official title:

Quetiapine for Bipolar Disorder and Alcohol Dependence

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00457197
• Other study ID #: 112006-046
• Status: Completed
• Phase: Phase 4
• First received: April 4, 2007
• Last updated: April 1, 2016
• Start date: March 2007
• Est. completion date: July 2011

Study information

• Verified date: April 2016
• Source: University of Texas Southwestern Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out whether an investigational drug called quetiapine can treat bipolar disorder, improve mood and reduce alcohol use and craving.

Description:

The primary aim in the study is to determine if quetiapine treatment is associated with greater reduction in alcohol use than placebo in outpatients with bipolar disorder and alcohol dependence. We will also examine if quetiapine treatment is associated with greater reduction in alcohol craving than placebo in outpatients with bipolar disorder and alcohol dependence and if quetiapine treatment is associated with greater improvement in depressive symptoms than placebo in outpatients with bipolar disorder and alcohol dependence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 90
• Est. completion date: July 2011
• Est. primary completion date: July 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Outpatients with a diagnosis of bipolar I or II disorder, depressed or mixed phase on the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID) and confirmed by interview with PI or co-I.

• Current diagnosis of alcohol dependence.

• Alcohol use (by self-report) of at least 15 drinks in the 7 days prior to baseline.

• Currently taking a mood stabilizer defined as lithium, divalproex/valproic acid, oxcarbazepine, or lamotrigine at a stable dose for > 14 days.

• Men and women age 18-65 years old.

• English or Spanish speaking.

Exclusion Criteria:

• Bipolar disorders other than bipolar I or II (e.g., not otherwise specified or cyclothymic disorders) based on the SCID and confirmed through clinical assessment by PI or co-I.

• Baseline Young Mania Rating Scale (YMRS) score > 35 or Hamilton Depression Rating Scale (HRSD) 17 score > 35.

• Current clinically significant psychotic features (hallucinations, delusions, disorganized thought processes).

• Evidence of clinically significant alcohol withdrawal symptoms defined as a Clinical Institute Withdrawal Assessment (CIWA-AR) score of > 8.

• History of hepatic cirrhosis or baseline AST or ALT > 3X upper limit of normal or other clinically significant findings on physical or laboratory examination.

• Mental retardation or other severe cognitive impairment.

• Prison or jail inmates.

• Pregnant or nursing women or women of childbearing age who will not use oral contraceptives, abstinence, or other acceptable methods of birth control during the study.

• Antipsychotic therapy within 14 days prior to randomization.

• Current carbamazepine or benzodiazepine therapy.

• Current treatment with medications shown to reduce alcohol consumption (naltrexone, acamprosate, disulfiram, or topiramate) in large randomized, controlled trials.

• Initiation of antidepressants or mood stabilizers or psychotherapy within past 2 weeks.

• High risk for suicide, defined as any suicide attempts in the past 3 months or current suicidal ideation with plan and intent.

• Intensive outpatient treatment for substance abuse (AA, NA meetings, or other 12-step programs or weekly psychotherapy that started at least 14 days prior to randomization will be allowed).

• Current treatment with ketoconazole, itraconazole, erythromycin, or nefazodone.

• Severe or life-threatening medical condition (e.g., congestive heart failure, terminal cancer) or laboratory or physical examination findings consistent with serious medical illness (e.g., severe edema, atrial fibrillation, dangerously abnormal electrolytes).

• Diabetes mellitus by history or suspected from baseline blood sugar.

• History of cataracts or suspected cataracts on ophthalmic exam

• History of seizure disorder of any etiology; if a subject develops a seizure episode, s/he will be discontinued from the study.

Related Conditions & MeSH terms

• Alcohol Dependence
• Alcoholism
• Bipolar Disorder
• Disease

Intervention

Drug:
• Placebo
Inactive ingredient matching the active medication in appearance.
• Quetiapine
Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.

Locations

Country	Name	City	State
United States	Psychoneuroendocrine Research Program	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Texas Southwestern Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Standard Drinks/Day Will Serve as the Primary Outcome Measure.		12 weeks
Secondary	Percent of Heavy Drinking Days		12 weeks
Secondary	Gamma-glutamyltransferase (GGT)	GGT is a liver enzyme measurement (IU/I)	12 weeks
Secondary	Aspartate Aminotransferase (AST)	AST is a liver enzyme measurement (IU/I)	12 weeks
Secondary	Alanine Aminotransferase (ALT)	ALT is a liver enzyme measurement (IU/I).	12 weeks
Secondary	Hamilton Rating Scale for Depression (HRSD)	The assessment is a clinician administered rating of depression with 17 questions. The total score is indicates level of depression within the following ranges: none (0-5), mild (6-10), moderate (11-15), severe (16-20), and very severe (21+).; Scale: Minimum: 0 Maximum: 50 Lower score associated with better outcome	12 weeks
Secondary	Inventory of Depressive Symptomatology-Self Report (IDS-SR)	IDS-SR is a self reported 30 item assessment to diagnose a major depressive episode.; Score: Minimum: 0 Maximum: 84 Lower score associated with better outcome	12 weeks
Secondary	Young Mania Rating Scale (YMRS)	This is an 11-item, observer rated measure of the severity of manic symptoms on a 5 point scale. The total score indicates overall severity of mania with a minimum of zero (indicating normalcy) and a maximum of 60 (indicating very severe).; Score: Minimum: 0 Maximum: 60 Lower score associated with better outcome	12 weeks
Secondary	Penn Alcohol Craving Scale (PACS)	The PACS is a five-item self-administered instrument for assessing craving, frequency, intensity, and duration of thoughts about drinking are assessed along with ability to resist drinking; Score: Minimum: 0 Maximum: 30 Lower score associated with better outcome.	12 weeks